Analyzing Kyntra Bio (KYNB) and Its Rivals

Kyntra Bio (NASDAQ:KYNB) is one of 458 public companies in the “Pharmaceutical Preparations” industry, but how does it weigh in compared to its peers? We will compare Kyntra Bio to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Kyntra Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1	1	0	1	2.33
Kyntra Bio Competitors	4898	9970	16002	378	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 67.26%. Given Kyntra Bio’s peers stronger consensus rating and higher possible upside, analysts clearly believe Kyntra Bio has less favorable growth aspects than its peers.

Institutional & Insider Ownership

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 2.0% of Kyntra Bio shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Kyntra Bio and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kyntra Bio	$8.30 million	-$47.58 million	0.13
Kyntra Bio Competitors	$432.18 million	-$67.78 million	-10.47

Kyntra Bio’s peers have higher revenue, but lower earnings than Kyntra Bio. Kyntra Bio is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Kyntra Bio has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Kyntra Bio’s peers have a beta of 5.62, indicating that their average share price is 462% more volatile than the S&P 500.

Profitability

This table compares Kyntra Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,598.55%	N/A	-26.27%
Kyntra Bio Competitors	-2,662.44%	-364.10%	-42.99%

Summary

Kyntra Bio beats its peers on 7 of the 13 factors compared.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.